Higher blood levels of soluble interleukin 7 receptor subunit alpha (sIL-7R alpha) — a portion of a receptor protein involved in inflammation — significantly associate with lower disease activity in people with ANCA-associated vasculitis (AAV), a small study found. These preliminary findings suggest that the soluble receptor protein “can…
Soluble IL-7R alpha in blood seen as possible biomarker of AAV activity
Immune T-cells positive for the GPR56 receptor protein — a marker for cell-killing immune cells — may contribute to local tissue damage in ANCA-associated vasculitis (AAV) patients whose disease is associated with antibodies against the proteinase 3 (PR3) protein, a study showed. Notably, these cells were more likely to…
Cardiovascular events like a heart attack are more likely in people with ANCA-associated vasculitis (AAV) who also have diabetes, a study reported. Other identified risk factors for AAV patients, a group known to be at cardiovascular disease risk, included older age and a prior history of cardiovascular problems. “Treatment…
The first week of February, I turned 35. It was a typical, uneventful adult birthday — especially because it fell on a Monday. I happened to be traveling back from a weekend of out-of-state work, so besides some good wishes from family and friends, there wasn’t a huge celebration. (At…
Tavneos (avacopan) effectively reverses severe kidney disease associated with ANCA-associated vasculitis (AAV) compared with standard steroid therapy, according to a subgroup analysis of the Phase 3 ADVOCATE clinical trial. Greater improvements in kidney function with Tavneos were sustained for the two months of follow-up after the treatment stopped.
Living with a rare disease, by its nature, is isolating. According to the National Organization for Rare Disorders, a rare disease is one that affects fewer than 200,000 Americans. There are currently over 7,000 such diseases. I’ve lived with ANCA vasculitis, a subset of autoimmune diseases that affects…
Tavneos (avacopan) has been approved in Australia as an add-on oral therapy for adults with two main types of ANCA-associated vasculitis (AAV): microscopic polyangiitis (MPA) and granulomatosis polyangiitis (GPA). The approval from Australia’s Therapeutic Goods Administration specifically covers the use of Tavneos in combination with rituximab or…
Rates of relapse, and mortality, are higher in people with eosinophilic granulomatosis with polyangiitis (EGPA) that affects the gastrointestinal (GI) tract — and periods of remission less likely — relative to EGPA patients without GI involvement, according to a study in China. Those with GI involvement also presented with…
Preventive, or prophylactic treatment with certain antibiotics can reduce the risk of severe infections for people with ANCA-associated vasculitis (AAV) who are receiving immunosuppressive treatment, a new analysis shows. Specifically, good results were found in a clinical trial with a combination of antibiotics known as TMP/SMX. “This … is…
When the world outside of your head becomes overwhelming and you need to cling to something for support, where do you find your center? With vasculitis, that world is an unfamiliar one. It’s full of new challenges, new details a patient is obligated to learn for their own…
Recent Posts
- Kidney tissue patterns may influence treatment response in AAV
- Chronic lung condition doubles infection risk in AAV patients: Study
- I often can’t breathe automatically due to lung issues and AAV
- New kidney risk score shows strong predictive power in AAV study
- Half of adults with AAV have interstitial lung disease at diagnosis, study finds